Trial Profile

Impact of the Introduction of ORKAMBI on Anxiety, Depression, Quality of Life and Adherence of Adolescents and Young Adults

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 07 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ivacaftor/lumacaftor (Primary)
Indications Cystic fibrosis
Focus Therapeutic Use
Acronyms ORKAJA

Most Recent Events

02 Feb 2023 Status changed from active, no longer recruiting to completed.
31 Mar 2021 Planned number of patients changed from 60 to 19.
31 Mar 2021 Planned End Date changed from 1 Dec 2018 to 1 Dec 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com